After the highly successful congress held in Milan in 2012, Euroretina has once again organised its annual event, which over the successive years has now become an essential date in the agenda of all European specialists in this area.
With a steady increase in the number of participants over the twelve annual Euroretina editions, the 13th congress is to be held in Hamburg from the 26th to the 29th September, following last year’s meeting in Milan which was attended by 3,500 ophthalmologists.
Dr. Monés, Medical Director of the Barcelona Macula Foundation, will be a distinguished participant at the event, taking part in a plenary session on dry AMD on Friday 27th, together with other renowned international experts. In the session, Dr. Mones will present the conclusions of an article published recently in the journal Ophthalmology, under the title “Optical Coherence Tomography Assessment of Apparent Foveal Swelling in Patients with Foveal Sparing Secondary to Geographic Atrophy”.
In this work, Dr Mones and the researchers Dr. F. Trindade and Marc Biarnes reveal that by determining the presence of foveal swelling in patients with dry AMD by spectral domain OCT, the different layers of the retina can be studied with the highest precision. The results are especially important since “in order to be able to apply new treatments and to distinguish the effects of new medicinal products it is essential for scientific findings at a histological level, and of layers of retinal cells, to be well classified” mentioned Dr. Jordi Monés.
Dr. Kuppermann, a member of the scientific committee of the Barcelona Macula Foundation, will also participate as a speaker in the Conference scientific program, in the round table on retinal vein occlusion that takes place at midday on Saturday 28th.
Dr. Monés will also be active on several advisory boards and in working groups designed to help young professionals to improve the clinical practice of some techniques, such as intravitreous injections. The objective of the taskforce in which the Director of the Foundation takes part is to inform the ophthalmologic community about the steps to take in the highest risk procedures and to optimize the techniques to reduce the risk as far as possible.
One of the advisory boards in which Dr. Monés participates concerns the new medicinal product JETREA, which is designed to prevent the need for surgery in patients with sight-threatening macular traction.
World Retina Day
Moreover, this year’s Euroretina congress will host the official launch of World Retina Day, an initiative promoted by the most important scientific societies to provide information and relevant news about retinal medicine and surgery. Spain is represented by the Spanish Retina and Vitreous Society (SERV, Sociedad Española de la Retina y el Vítreo), which will be present on Saturday 28th during the launch of World Retina Day.